Cytokines, Janus Kinase Inhibitors, and Small-Molecule Therapies, Oh My!: New Inroads Into Rheumatoid Arthritis Management

Although the introduction of biologic agents has transformed treatment paradigms for rheumatoid arthritis (RA), a considerable proportion of patients do not respond sufficiently to these therapies. A potential new therapeutic alternative for these patients is small-molecule inhibitors, which offer targeted inhibition of intracellular pathways that can be achieved via oral administration. To realize the benefits of small-molecule inhibitor therapy, it is essential for clinicians to know how these agents target cytokine signaling and intracellular pathways.  
 
This activity contains three interactive modules designed to help clinicians understand the mechanisms of action of small-molecule inhibitors and to recognize how these agents fit into established RA management guidelines.
 
Medium: Online Interactive Modules

Commercial Support: Support for this activity has been provided through an independent educational grant from Pfizer.

Learning Objectives and Target Audience

At the conclusion of this activity, the participant will be able to:

  • Describe the role of cytokine signals and pathways in driving inflammation in RA;
  • Summarize the differences between small-molecule inhibitors and biologics in RA treatment;
  • Evaluate recent clinical advances with the use of small-molecule inhibitors for RA and their potential implications for clinical practice.
This activity has been designed to meet the educational needs of rheumatologists and other health care providers who are involved in the care of patients with RA.
Additional information
ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
For more information, please contact:
CME Coordinator Contact Name: 
RedMedEd
CME Coordinator Contact Email: 
CME Coordinator Contact Phone: 
(610) 251-6841
Summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Participation
Activity opens: 
08/02/2017
Activity expires: 
08/02/2018

PROGRAM CHAIR

  Anisha B. Dua, MD, MPH
  Assistant Professor, Department of Rheumatology
  Fellowship Program Director
  Director of the Vasculitis Center
  University of Chicago
  Chicago, Illinois
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Credit Designation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicne and RedMedEd. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
The University of Chicago Pritzker School of Medicne designates this enduring material for a maximum of .75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Period

Activity opens: 
08/02/2017
Activity expires: 
08/02/2018

Registration: To view this activity, you will need to visit the RedMedEd website.
Click here to view the activity or if you are logged in click on the "Complete Activity" button!

Please login or create an account to take this course.